Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized its offering and priced approximately 2,000,000,000 (equivalent). Teva expects to use the net proceeds from the offerings (i) to fund the announced tender offers (collectively, the “Tende ...